Gap Inc vs Twist Bioscience Corp — how do they compare? Gap Inc trades at $23.33 (market cap $8.29B), while Twist Bioscience Corp trades at $156.75 (market cap $10.32B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Gap Inc pays a 2.96% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Twist Bioscience Corp for 27 Days on average.
| GAP | TWST | |
|---|---|---|
Market Cap | $8.29B | $10.32B |
Volume | 5,470,564 | 5,894,998 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $205.00 |
52-Week Low | $18.35 | $25.45 |
Typical Hold Time | 37 Days | 27 Days |
Enterprise Value | $11.53B | $10.24B |
Dividend Yield | 2.96% | — |
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.36, down 1.81% for the day, with a bullish technical outlook from moving averages. The company shows strong profitability with a 43.26% gross margin and 8.14% net margin, supported by recent earnings beats. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B. Recent news highlights brand revitalization efforts, including music partnerships and board appointments, signaling strategic moves to engage customers.
The outlook is positive given low valuations (P/E 7.11, P/S 0.58) and analyst consensus target of $25.67, implying upside. Risks include reliance on Old Navy's turnaround and competitive pressures. Institutional activity is mixed, with some funds reducing stakes while others increase positions, reflecting cautious optimism.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →